Pharmaceutical marketing, research and development company Breckenridge Pharmaceutical has signed a deal to acquire certain assets of Pernix Therapeutics' subsidiary, Cypress Pharmaceuticals, for $30m. The assets included in the agreement ...
Pernix Therapeutics has entered into a definitive agreement to acquire Cypress Pharmaceuticals and Hawthorn Pharmaceuticals in Madison, Mississippi, US. Hawthorn offers branded drugs including allergy, respiratory, iron deficiency, ...
Tags: Pernix Therapeutics, Cypress Pharmaceuticals, Hawthorn Pharmaceuticals
Pernix Therapeutics Holdings has reported a net loss of $270,342, or $0.01 per share, for the third quarter ended 30 September 2012 compared to a net income of $1.99m, or $0.08 per share, for thesame period in 2011. Net sales for the ...